Aptose Biosciences Inc.

Climate Impact & Sustainability Data (2016, 2023)

Short-term Goals:

History of operating losses and lack of product revenue.
Early stage of development with no products having obtained regulatory approval.
Need to raise additional capital, potentially leading to dilution.
Reliance on contract manufacturers with limited control.
Delays in clinical testing and regulatory approvals.
Competition from established companies with greater resources.
Uncertainty in patent protection and potential infringement.
Exposure to product liability and other claims.
Difficulty in enrolling patients in clinical trials.
Dependence on key personnel.
Potential for employee misconduct.
Exposure to exchange rate risk.
Risks associated with acquisitions, collaborations, and in-licensing.
Negative results from clinical trials or studies of others.
Data security incidents and privacy breaches.

Prioritization of resources towards the development of CG’806 and temporary delay of clinical activities with APTO-253.
Development of a new soluble and stable formulation for APTO-253 to address filter clogging issues.
Engagement with the FDA to address the clinical hold on APTO-253.
Use of multiple CMOs for manufacturing.
Implementation of confidentiality procedures to protect intellectual property.
Seeking additional collaborative arrangements to develop and commercialize products.
Investment in data and information technology security.
Maintaining bank accounts with Schedule I banks and investing only in highly rated Canadian securities.

Frameworks Used: IFRS

Third-party Assurance: KPMG LLP

Substantial doubt about the company's ability to remain a going concern over the next twelve months.
Intense competition and technological change in the biotechnical and pharmaceutical industries.
Difficulty in enrolling patients for clinical trials.
Reliance on contract manufacturers and the potential for quality, cost, or delivery issues.
Risks associated with international trade and foreign markets.
Potential for negative results from clinical trials or studies of others.
Potential for product liability, clinical trial liability, or environmental liability claims.
Potential for failure to obtain partnerships for product candidates.

Plans to raise additional funds through equity financing, debt issuances, collaboration agreements, or corporate partnerships.
Development of a new G3 formulation of luxeptinib to address limited absorption issues.
Contracting with alternate suppliers to mitigate manufacturing risks.
Implementation of confidentiality procedures to protect intellectual property.
Obtaining product liability insurance coverage for clinical trials.
Seeking additional collaborative arrangements to develop and commercialize products.